Contrasting BioCardia (BCDA) & Its Competitors
by Jessica Moore · The Cerbat GemBioCardia (NASDAQ:BCDA – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare BioCardia to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
Insider & Institutional Ownership
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares BioCardia and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioCardia | N/A | -$8.23 million | -1.39 |
| BioCardia Competitors | $735.05 million | $13.62 million | -14.86 |
BioCardia’s rivals have higher revenue and earnings than BioCardia. BioCardia is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and recommmendations for BioCardia and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| BioCardia Competitors | 9800 | 15084 | 45398 | 1579 | 2.54 |
BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,708.99%. As a group, “Biotechnology” companies have a potential upside of 104.02%. Given BioCardia’s higher probable upside, equities analysts clearly believe BioCardia is more favorable than its rivals.
Profitability
This table compares BioCardia and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -569.36% | -183.15% |
| BioCardia Competitors | -12,359.35% | -203.09% | -30.93% |
Risk and Volatility
BioCardia has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, BioCardia’s rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.
Summary
BioCardia rivals beat BioCardia on 9 of the 13 factors compared.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.